LYELL IMMUNOPHARMA INC (LYEL)
US55083R1041 - Common Stock
| MRQ (2024-9-30) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 100.30M | 145.65M | 123.60M | 293.80M | 140.40M | |||
| Marketable Securities | 340.25M | 400.58M | 516.60M | 321.00M | 472.20M | |||
| Other Current Assets | 9.50M | 8.46M | 11.10M | 11.50M | 4.90M | |||
| Total Current Assets | 450.05M | 554.69M | 651.30M | 626.30M | 617.50M | |||
| Non-Current Assets | ||||||||
| PPE Net | 124.71M | 142.32M | 166.30M | 166.60M | 124.10M | |||
| Investments And Advances | 39.11M | 48.51M | 115.00M | 330.50M | 163.40M | |||
| Other Non-Current Assets | 5.35M | 4.52M | 5.00M | 3.90M | 3.20M | |||
| Total Non-Current Assets | 169.17M | 195.34M | 286.30M | 501.10M | 290.80M | |||
| TOTAL ASSETS | 619.22M | 750.03M | 937.60M | 1.13B | 908.30M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Accrued Expenses | 29.01M | 26.63M | 26.40M | 27.60M | 27.00M | |||
| Accounts Payable | 3.60M | 4.82M | 3.90M | 3.20M | 9.40M | |||
| Other Current Liabilities | 907.00K | 3.07M | 6.70M | 15.90M | 12.90M | |||
| Total Current Liabilities | 33.51M | 34.52M | 37.00M | 46.70M | 49.30M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Other Non-Current Liabilities | 55.01M | 60.56M | 67.30M | 150.90M | 140.60M | |||
| Total Non-Current Liabilities | 55.01M | 60.56M | 67.30M | 150.90M | 140.50M | |||
| TOTAL LIABILITIES | 88.52M | 95.08M | 104.30M | 197.60M | 189.80M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -1.15B | -1.00B | -767.50M | -584.40M | -334.10M | |||
| Additional Paid In Capital | 1.68B | 1.66B | 1.61B | 1.52B | 41.40M | |||
| Common Shares | 26.00K | 25.00K | 0.00 | 0.00 | 1.01B | |||
| Other Shareholders' Equity | 760.00K | -94.00K | -7.60M | -1.60M | 300.00K | |||
| Shares Outstanding | 256.56M | 253.96M | 249.60M | 242.70M | 242.80M | |||
| Tangible Book Value per Share | 2.07 | 2.58 | 3.34 | 3.83 | -1.21 | |||
| Total Shareholders' Equity | 530.70M | 654.95M | 833.30M | 929.80M | 718.40M | |||
| TOTAL LIABILITIES AND EQUITY | 619.22M | 750.03M | 937.60M | 1.13B | 908.30M | |||
| Statistics | ||||||||
| Current Ratio | 13.43 | 16.07 | 17.60 | 13.41 | 12.53 | |||
| Return On Assets (ROA) | -32.94% | -31.28% | -19.53% | -22.19% | -22.51% | |||
| Return On Equity (ROE) | -38.44% | -35.82% | -21.98% | -26.91% | -28.46% | |||
All data in USD , ROIC based on taxRate of 0.21